Creative Biolabs is an undisputed leading provider of antibody development and generation services. Now, we provide in vitro diagnostic (IVD) antibody development services targeting various biomarkers of a wide variety of diseases. Especially, Creative Biolabs offers high-quality antibody development services for diagnostic applications targeting Von Willebrand factor (vWF) as a potential biomarker of sepsis.
Von Willebrand Factor (vWF)
The von Willebrand factor (vWF) is a blood glycoprotein that is important for platelet-platelet and platelet-vessel hemostatic interactions. It is deficient or defective in von Willebrand disease and is involved in a large number of other diseases, including thrombotic thrombocytopenic purpura, Heyde's syndrome, and possibly hemolytic-uremic syndrome. Increased plasma levels in a large number of cardiovascular, neoplastic, and connective tissue diseases are presumed to arise from adverse changes to the endothelium and may contribute to an increased risk of thrombosis. Hereditary or acquired defects of vWF lead to von Willebrand disease (vWD), a bleeding diathesis of the skin and mucous membranes, causing nosebleeds, menorrhagia, and gastrointestinal bleeding. The point at which the mutation occurs determines the severity of the bleeding diathesis.
Decreased VWF antigen may be seen in association with congenital von Willebrand disease, acquired VWD that may be associated with monoclonal gammopathies, lymphoproliferative disorders, autoimmune disorders, and hypothyroidism. Increased VWF antigen may be seen in pregnancy or estrogen use, inflammation and liver disease.
Fig. 1 Structure of von Willebrand factor.1
Von Willebrand Factor Antigen of Sepsis Infections
Von Willebrand Factor antigen (vWf-Ag) is a macromolecular antigen that is produced predominantly by endothelial cells and to a lesser extent by platelets. In the setting of endothelial activation or injury, VWF is released from preformed stores into the circulation. VWF has been investigated as a biological marker of endothelial injury in patients both at risk for and with established ALI/ARDS. In one study of patients with sepsis, plasma VWF levels had predictive value for the development of ARDS. It may be used as a predictive plasma marker for the development of acute lung injury in patients with nonpulmonary sepsis.
IVD Antibody Development Services Targeting vWF Marker
IVD antibodies are extensively used in immunodiagnostic tools for disease screening and therapeutic monitoring. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to develop high-quality anti-vWF antibodies. Besides antibody generation, Creative Biolabs also offers diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, assay optimization, and kit production.
Creative Biolabs has successfully completed numerous IVD antibody generation and development projects for clients across the globe. Please contact us to discuss your specific requirements and experience the great value of our expert services.
Reference
For Research Use Only.
